Detalhe da pesquisa
1.
HIV rebound in HIV controllers is associated with a specific fecal microbiome profile.
Eur J Immunol
; : e2350809, 2024 May 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38727191
2.
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial.
Infection
; 51(5): 1273-1284, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-36648627
3.
New Proteomic Signatures to Distinguish Between Zika and Dengue Infections.
Mol Cell Proteomics
; 20: 100052, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33582300
4.
Utility and Impact of the Implementation of Same-Day, Self-administered Electronic Patient-Reported Outcomes Assessments in Routine HIV Care in two North American Clinics.
AIDS Behav
; 26(7): 2409-2424, 2022 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-35064851
5.
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1.
Clin Infect Dis
; 72(11): e815-e824, 2021 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33043969
6.
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
Clin Infect Dis
; 71(12): 3110-3117, 2020 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31879782
7.
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection.
Clin Infect Dis
; 71(5): 1255-1262, 2020 08 22.
Artigo
Inglês
| MEDLINE | ID: mdl-31769793
8.
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.
N Engl J Med
; 373(8): 714-25, 2015 Aug 20.
Artigo
Inglês
| MEDLINE | ID: mdl-26196502
9.
12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
Clin Infect Dis
; 62(12): 1489-96, 2016 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-27025835
10.
Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies.
J Virol
; 88(21): 12385-96, 2014 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-25122785
11.
Interleukin-7 promotes HIV persistence during antiretroviral therapy.
Blood
; 121(21): 4321-9, 2013 May 23.
Artigo
Inglês
| MEDLINE | ID: mdl-23589672
12.
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Lancet
; 382(9893): 700-8, 2013 Aug 24.
Artigo
Inglês
| MEDLINE | ID: mdl-23830355
13.
Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment.
HIV Clin Trials
; 15(6): 269-73, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-25433666
14.
Burkholderia cepacia: A Rare Source of Endocarditis.
R I Med J (2013)
; 107(1): 23-25, 2024 Jan 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38166072
15.
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.
Lancet HIV
; 2024 May 08.
Artigo
Inglês
| MEDLINE | ID: mdl-38734016
16.
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study.
Lancet HIV
; 11(3): e146-e155, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38307098
17.
Triple Threat: Triple Pathogen Endocarditis.
Cureus
; 15(10): e47860, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-38021926
18.
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
Lancet HIV
; 10(1): e15-e23, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36566079
19.
Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.
Open Forum Infect Dis
; 10(3): ofad101, 2023 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-36968959
20.
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Lancet HIV
; 10(9): e566-e577, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37567205